TTK Healthcare Ltd
NSE: TTKHLTCARE BSE: 507747
₹908.25
(-0.89%)
Wed, 04 Mar 2026, 04:10 am
Market Cap12.91B
PE Ratio21.37
Dividend1.09
Health Technology
Pharmaceuticals: Major
24.5KTTK Healthcare Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are well covered by earnings (2.4x coverage).
- Dividends per share have been stable in the past 10 years.
- TTK Healthcare's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- TTK Healthcare's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- TTK Healthcare is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- TTK Healthcare is profitable, therefore cash runway is not a concern.
- TTK Healthcare is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (71.7%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 10x debt.
- TTK Healthcare's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (35% vs 11.9% today).
- TTK Healthcare earns more interest than it pays, coverage of interest payments is not a concern.
- TTK Healthcare's level of debt (11.9%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the TTK Healthcare board of directors is about average.
- T.'s remuneration is higher than average for companies of similar size in India.
- T.'s compensation has increased by more than 20% in the past year whilst earnings fell less than 20%.
misc
- TTK Healthcare is not covered by any analysts.
- TTK Healthcare has significant price volatility in the past 3 months.
past
- TTK Healthcare's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
- TTK Healthcare's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- TTK Healthcare used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- TTK Healthcare's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- TTK Healthcare has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- TTK Healthcare's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- TTK Healthcare's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- TTK Healthcare's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- TTK Healthcare is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- TTK Healthcare is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- TTK Healthcare is overvalued based on earnings compared to the India market.
- TTKHLTCARE underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- TTKHLTCARE underperformed the Market in India which returned -14.5% over the past year.
- NSEI:TTKHLTCARE is down -1.4% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:TTKHLTCARE is down -1.4% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800